OBJECTIVE： To evaluate the pharmacoeconomics characteristic of olmesartan medoxomil in ARB anti-hypertension drugs， and to provide reference for clinical drug use. METHODS： The literatures on the pharmacoeconomics study of olmesartan medoxomil published from Jan. 2002 to Dec. 2013 were searched with assigned search strategy from domestic and international databases like CNKI， PubMed， etc.， and comprehensive comparison and consistency analysis were conducted. RESULTS： 4 literatures about pharmacoeconomics study of olmesartan medoxomil in different countries were screened， with essential hypertension patients as target population cost-minimization analysis or cost-effectiveness analysis as method， and 9 months-5 years as study course. The results consistency was well and showed the treatment cost of olmesartan medoxomil was usually less or better cost-effectiveness. CONCLUSIONS： Olmesartan medoxomil shows pharmacoeconomics advantage among ARBs drugs based on existed literature review.